About us _____________________________________________________
10 Year anniversary
NMX’s success relies on our diverse team of experts and streamlined biophysics platform, which pairs advanced NMR techniques along with orthogonal biophysical methods, curated libraries, biochemical assays, and virtual screens. Our established workflow allows us to confidently determine the key properties for your hit-to-lead and hit validation projects.
It has been an amazing decade helping our research partners achieve their goals in fragment-based lead discovery – thank you! We look forward to many more partnerships and innovations throughout the coming years.
___________________________________________________ NMX News
Publication
Our latest publication is now available in Bio-organic Chemistry! A collaborative effort alongside the University of Minnesota, The Broad Institute, and 3 Point Bio, this work explores the characterization of histidine kinase (HK) inhibitors and their role in antibiotic resistance strategies. NMX studied these inhibitors and their binding at the active site by numerous NMR methods, including 1D 1H, 19F, STD, T2-CPMG, 2D 1H-15N TROSY-HSQC, and their structure-activity relationships were explored. These compounds were found to inhibit HK, indicating a promising alternate pathway for combating antibiotic resistance via anti-virulence effects.
Recent Events ________________________________________________
MOOT Symposium
NMX founder Steven LaPlante was a plenary speaker at this past weekend’s 35th MOOT NMR Symposium, which happened on October 19th-20th, 2024, at McGill University in Montréal.MOOT is an annual event for NMR spectroscopists to present and discuss their work in the field, bringing together scientists from across Canada.
Along with Steven, NMR specialist Paul White was in attendance, bringing their extensive expertise in NMR for fragment-based lead discovery to MOOT. It was fantastic to meet NMR researchers and discuss the latest in the field!
__________________________________________________________________________________
RNA Canada 2024
NMX recently attended the RNA Canada ARN 2024 meeting, which took place in Ottawa from September 30th - October 4th, 2024. Interest in development of RNA-based therapies has grown significantly since the COVID19 pandemic, leading to the central concept of this conference: “tools for better life”. With this in mind, was crucial to bring together top experts in RNA to share ideas for developing new tools and methods.
An active participant in this field, NMX is currently developing methodologies to better characterize the structures, dynamics, interactions, and other key properties of RNA biological activities. Myriam Létourneau presented ongoing biological research and method implementation within NMX’s biophysics platform.
__________________________________________________________________________________
FBLD 2024
NMX was delighted to attend the Fragment-Based Lead Discovery (FBLD 2024) conference held in Boston from September 22nd-25th, 2024. This multi-disciplinary event covered a range of topics related to fragment-based lead discovery, bringing together the experts in the field from North America and beyond.
NMX founder Steven LaPlante presented about the critical role that NMR plays in discovering hits and leads within FBLD. Alongside NMR, NMX's complete biophysical platform allows for structure-activity relationships to be established, helping to reduce resources and time spent on drug discovery projects.
______________________________________________________ NMX Upcoming Events
32nd Protein Structure Determination in Industry
Steven LaPlante will be presenting at the 32nd Protein Structure Determination in Industry (PSDI) conference, taking place on November 10th-12th, 2024, in Paris, France.
Spanning over three decades in the field of pharmaceutical research, Steven will be sharing his personal experience and insights regarding the use of structural biology to guide drug discovery. As the elucidation of protein-ligand interactions is crucial for effective drug designing strategies, case studies of various target proteins will be presented to illustrate this concept.
__________________________________________________________________________________
CERMO-FC Annual Symposium
The NMX team will be present at the Annual Symposium of the Centre d’Excellence en Recherche sur les Maladies Orphelines – Fondation Courtois (CERMO-FC) on November 21st-22nd, 2024, at the UQAM Science Pavillion in downtown Montreal.
This event will bring together researchers with interests in biomedical and pharmaceutical research, with aims of sharing knowledge and ideas to help combat complex and rare diseases. The goal of this meeting is to identify novel targets for therapeutic approaches to patient care, increasing quality of life and outcomes for affected individuals.
NMX is proud to be a sponsor at such an impactful symposium – we hope to see you there!
NMX Research and Solutions, Inc. 500, Boulevard Cartier Ouest, Suite 6000 Laval, Québec, Canada H7V 5B7
Follow us on LinkedIn: https://www.linkedin.com/company/nmx-research-and-solutions-inc/
Follow us on X : https://x.com/NMX_Research
Kommentare